35 results about "Venom Protein" patented technology

The invention provides a predatory mite venom protein or a spider venom protein. The amino acid sequences of the predatory mite venom protein and the spider venom protein are selected from SEQ ID NO.1-8 or any one of SEQ ID NO.1-8 with 95% or more of identity. Tetranychus urticae tests show that after spraying treatment, the predatory mite poison protein or spider poison protein provided by the invention achieves a 100% lethal effect within 48 hours, and is a known protein pesticide with the highest tetranychus urticae lethal rate at present. The predatory mite poison protein or spider poison protein provided by the invention has high specificity to spider mites, is mild and harmless to human bodies and other organisms in the environment, can be used in farmlands, gardens and even family potted plants, and can be naturally degraded; the production process is simple and efficient, and has the potential of large-scale application.

The invention provides fusion protein containing snake venom protein and application of the fusion protein in biosynthesis of stable isotope labeled snake venom protein, and belongs to the technical field of genetic engineering and protein preparation. The fusion protein comprises a 6-poly-histidine tag, a fusion tag, a restriction enzyme cutting site of WELQ protease and snake venom protein which are connected in sequence. According to the fusion tag, the solubility of the snake venom protein fusion protein can be improved; the 6-poly-histidine tag and the fusion tag can be removed through enzyme digestion of WELQ protease, the enzyme digestion removal effect is good, and the natural structure and activity of the snake venom protein can be guaranteed; besides, a culture medium containing a unique nitrogen source or a unique carbon source labeled by an isotope is used for carrying out induction culture on recombinant bacteria for expressing the fusion protein, the fusion protein containing the target snake venom protein is subjected to induction expression, purification, WELQ protease digestion and the like are carried out, and the stable isotope labeled snake venom protein with the purity reaching 95% or above and the labeling efficiency exceeding 91% can be obtained.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

Techniques are provided for determining pan-HLA binding of viral proteins. A trained classifier model is operable to determine, independently per HLA, at least one of (a) an average binding prediction of overlapping peptides at each position of a viral protein, (b) a maximum value of a binding prediction of overlapping peptides at each position of the viral protein, (c) standard deviation of a binding prediction of overlapping peptides at each position of the viral protein, and (d) a combination of one or more of (a)-(c). A classification engine uses the classifier model to determine average binding predictions of overlapping peptides at each position of the viral protein independently for test HLA-I and HLA-II functional groupings, where a peptide is classified as a binder when an average binding prediction corresponding to the peptide satisfies a binding value threshold.

The invention relates to a recombinant chikungunya virus vaccine as well as a preparation method and application thereof, in particular to a recombinant protein which comprises chikungunya virus protein or a variant thereof. The chikungunya fever virus serving as a main target of a neutralizing antibody is optimized, new nanoparticle protein is formed and used for preparing the vaccine, and the vaccine can stimulate an organism to generate the neutralizing antibody aiming at the chikungunya fever virus and prevent in-vivo infection and has a good neutralizing effect.

The present invention relates to an oligonucleotide comprising: a) a nucleotide sequence of a broom-kojin-ricin loop (SRL) of a eukaryotic / mammalian 60S ribosomal subunit wherein the SRL nucleotide sequence comprises at least one adenine; and b) at least one cut-dependent marker; wherein the oligonucleotide is a single strand. Preferably, the oligonucleotides form at least one loop structure or stem-loop structure. In another aspect, the invention relates to a method of detecting active shiga toxin in a sample, the method comprising the steps of: a) providing at least one oligonucleotide according to the invention; b) providing a sample of shiga toxin to be detected; c) incubating the sample with at least one single-stranded oligonucleotide; and d) detecting a labeled signal, wherein the signal indicates the presence of Shiga toxin in the sample. The invention additionally comprises a kit comprising at least one oligonucleotide according to the invention.

The application is based on machine learning model, and the polypeptide WFKDWY (166953) with potential is screened through polypeptide virtual screening technology based on the analysis of PEDV Nsp5 protein crystal structure. The sequence of 166953 is artificially synthesized by solid phase, and the polypeptide is screened by using artificially expressed PEDV Nsp5 protein through ELISA experiment. The affinity constant of the polypeptide and the target protein is identified by surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 166953 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by fluorescence quantitative PCR and indirect immunofluorescence experiment. The results show that the sequence 166953 can significantly inhibit the infection of PEDV.

The present application relates to a kind of HhUp140 of anthomyiidae trichogramma venom protein and its application, it relates to the field of protein engineering, its amino acid sequence is as shown in SEQ ID NO:1, the protein can be used to paralyze pest larvae, extend pest pupation period.The present application extends the pupation period of anthomyiidae trichogramma venom protein HhUp140, reduces the disease of crop by pest to some extent.

The present invention discloses a canine distemper virus H protein monoclonal antibody 6A4A6 and its application, which belongs to the field of monoclonal antibody technology. The present invention screened out 9 monoclonal antibodies through indirect ELISA and indirect immunofluorescence identification, and named them 2C1A1, 2D1B1, 6A4A5, 6A4A6, 6G4H1, 6G4H3, 6H4F4, 6H4H5 and 6H4H6 respectively. After indirect immunofluorescence identification, the 9 monoclonal antibodies obtained were all able to react with the vaccine strain (CDV-Onderstepoort); the neutralizing antibody test results showed that among the 9 monoclonal antibodies obtained, 6A4A5 and 6A4A6 did not react with giant panda / SX / 2014 (a highly toxic isolate), but only reacted with the vaccine strain, while 6A4A6 had a higher neutralizing titer than 6A4A5 (up to 2 6 ), which can be used to prepare detection reagents and therapeutic preparations for identifying canine distemper virus vaccine strains.

The application belongs to the field of biological medicine, and particularly relates to a kind of Bungarus multicinctus venom protein and a preparation method and application thereof.The application provides a new sperm motility promoter, which is derived from Bungarus multicinctus venom and has the application potential to be developed into a new sperm motility promoter.

This invention utilizes a machine learning model to analyze the S1-CTD region of the PEDV S protein crystal structure. Through virtual peptide screening, a peptide sequence of FWKEAK (110616) with potential affinity for the target protein was identified. The 110616 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV S1 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 110616 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 110616 sequence significantly inhibited PEDV infection.

The invention discloses an electrochemical sensor based on TdT enzyme and CbAgo synergistic mediation and application of the electrochemical sensor in cobra venom protein detection, and belongs to the technical field of electrochemical biosensors. Through magnetic bead enrichment, CbAgo protein cleavage and TdT extension reaction, and construction of a TdT enzyme and CbAgo protein synergistically mediated protein-nucleic acid conversion technology, a detection target is converted from cobra venom protein into a nucleic acid product, then the nucleic acid product is utilized to activate a Cas12a system to cut a probe P combined with a gold electrode, finally, the probe P is converted into an electrochemical signal, and the electrochemical signal is detected. The efficient and accurate detection of the cobra venom protein is realized. The electrochemical biosensor disclosed by the invention is high in sensitivity and good in specificity, and has extremely high application value in the aspects of accurate identification and quantitative analysis of cobra venom protein.

The present application relates to the technical field of veterinary biological products. Particularly provided are a porcine epidemic diarrhea virus S protein and a related product. The amino acid sequence of a porcine epidemic diarrhea virus S protein fragment is as shown in SEQ ID NO. 4. A trimer tag is fused at the C terminus of a protective antigen in a form of the truncated porcine epidemic diarrhea virus S protein, so as to construct a trimer S protein; and after expression and purification, animal evaluation is performed to determine the immunogenicity. Upon verification, a vaccine prepared from the trimer S protein has the advantages of high safety, good immunogenicity, batch-to-batch consistency, capability of inducing piglets to generate good immune responses, etc., and therefore can effectively treat or prevent porcine epidemic diarrhea.

The invention discloses a novel toxic protein and application thereof in mosquito control, and belongs to the technical field of biological control. The invention provides a novel toxic protein Cry50Ba2-like, the amino acid sequence of the novel toxic protein Cry50Ba2-like is as shown in SEQ ID NO.2, and the nucleotide sequence of a gene Cry50Ba2-like encoding the protein is as shown in SEQ ID NO.1. The invention further provides a preparation method of the novel toxic protein Cry50Ba2-like. According to the present invention, the protein Cry50Ba2-like is expressed and purified through the recombinant engineering strain, and the insecticidal activity determination experiment results prove that the protein has efficient insecticidal activity on culex quinquefasciata larvae, can be adopted as the environmentally-friendly biological insecticide, and provides the efficient and safe novel solution for mosquito-borne disease prevention and control.

The invention discloses an application of a sebastites verrucosa venom protein neoVTX. The invention finds that the sebastes verrucosa venom protein neoVTX has the functions of inhibiting a voltage-gated sodium ion channel and mediating muscle paralysis, can inhibit activities of zebra fish and grass goldfish, and can be used as a macromolecular probe template for exploring the voltage-gated sodium ion channel and explaining clinical symptoms of stab wounds of sebastes verrucosa; the compound can be further used for developing a medicine for paralyzing muscles and a medicine for relieving stabbing poisoning of sebastes verrucosa.

The invention discloses a method for extracting venom protein of miniature parasitic wasps, and relates to the technical field of biology. The extraction method comprises the following steps: carrying out anesthesia treatment on the glassogyne brilliant, putting the treated glassogyne brilliant in a buffer solution containing a protease inhibitor, and separating out venom organs; after the venom organ is subjected to low-temperature grinding and ultrasonication treatment, disulfide bonds in protein are reduced, alkylation modification is carried out, then the protein is aggregated through a solvent to form precipitates, and the miniature parasitic wasp venom protein is obtained through separation. The systematic venom protein collection and extraction process is established for the first time, and the operation bottleneck of micro insect venom research is broken through. The extraction efficiency and integrity of venom protein are remarkably improved through key technologies such as material taking process optimization, buffer solution protection, low-temperature grinding and ultrasonication.

Techniques are provided for determining pan-HLA binding of viral proteins. A trained classifier model is operable to determine, independently per HLA, at least one of (a) an average binding prediction of overlapping peptides at each position of a viral protein, (b) a maximum value of a binding prediction of overlapping peptides at each position of the viral protein, (c) standard deviation of a binding prediction of overlapping peptides at each position of the viral protein, and (d) a combination of one or more of (a)-(c). A classification engine uses the classifier model to determine average binding predictions of overlapping peptides at each position of the viral protein independently for test HLA-I and HLA-II functional groupings, where a peptide is classified as a binder when an average binding prediction corresponding to the peptide satisfies a binding value threshold.

The invention relates to the technical field of functional protein screening, in particular to an effector with a venom protein function and application thereof. The invention provides an effector with a venom protein function. The effector comprises an A0A2W1B606 protein, an A0A2W1BGQ7 protein, an A0A2W1BE44 protein, an A0A2W1B9V0 protein, an A0A2W1BFA8 protein or an I3QC11 protein. The invention further provides a preparation method of the effector. The effector obtained by screening has high-level metabolic activity, signal transduction function and venom protein function; the method plays a key role in the interaction process of phytophagous insects-host plants, such as participation in the process of cotton bollworm invading plants, regulation of the resistance of the plants to cotton bollworm larvae, targeted inhibition of phenylpropane metabolic pathways, induction of cotton bollworm preference colonization and the like.

The application discloses an electrochemical sensor based on TdT enzyme and CbAgo synergistically mediated and application thereof in detection of cobra venom protein, and belongs to the technical field of electrochemical biosensors.The application constructs a protein-nucleic acid conversion technology mediated by TdT enzyme and CbAgo protein through magnetic bead enrichment, CbAgo protein cleavage and TdT extension reaction, converts the detection target from cobra venom protein into a nucleic acid product, and then utilizes the nucleic acid product to activate a Cas12a system to cleave a probe P combined on a gold electrode, and finally converts into an electrochemical signal, so that efficient and accurate detection of the cobra venom protein is realized.The electrochemical biosensor has high sensitivity and good specificity, and has extremely high application value in accurate identification and quantitative analysis of the cobra venom protein.

The present invention discloses a method for regulating the synthesis of ectoine in Escherichia coli, which relates to the technical field of biomedicine. The method for regulating the synthesis of ectoine in Escherichia coli disclosed by the present invention constructs a tisB toxin protein expression vector pET28a(+)-p2-22-tisB with a gene fragment of the tisB toxin protein, and transfers it into an Escherichia coli engineering bacterium capable of synthesizing ectoine, so as to obtain an Escherichia coli engineering bacterium E. coli Ect pET28a(+)-p2-22-tisB that spontaneously inhibits the synthesis of ectoine, and at the same time can ensure normal synthesis of ectoine in the early stage. The nucleotide sequence of the gene fragment of the tisB toxin protein is as shown in SEQ ID NO.1. In the first three rounds of fermentation, the yield of ectoine is similar to that of the control engineering bacterium; after the seventh round, the yield of ectoine drops sharply to 2.575 g / L, and in the twentieth round of fermentation, the yield of ectoine is zero.

The present application relates to a kind of HhMAPK15 of anthocarposa larva parasitoid venom protein and its application, it relates to the field of protein engineering, its amino acid sequence is as shown in SEQ ID NO:1, the protein can be used to inhibit pest larva to continue development.The present application will be used to inhibit pest larva to continue development on anthocarposa larva parasitoid venom protein HhMAPK15, can reduce the disease of crop by pest to a certain extent.

The application is based on machine learning model, and the polypeptide YYRKWP (168510) with potential is screened through polypeptide virtual screening technology based on the analysis of PEDV Nsp5 protein crystal structure. The sequence of 168510 is artificially synthesized by solid phase, and the polypeptide is screened by using artificially expressed PEDV Nsp5 protein through ELISA experiment. The affinity constant of the polypeptide and the target protein is identified by surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 168510 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by fluorescence quantitative PCR and indirect immunofluorescence experiment. The results show that the sequence 168510 can significantly inhibit the infection of PEDV.

The invention discloses an application of six subunit proteins of sebastibastes roseus venom protein neoVTX. The invention finds that six subunit proteins of neoVTX can inhibit voltage-gated sodium ion channels and mediate muscle paralysis functions, and verifies that neoVTX can inhibit activities of zebra fish and grass goldfish and does not cause individual death. The invention provides a new direction for preparing a voltage-gated sodium ion channel macromolecular probe template and a muscle paralysis drug by using six subunit proteins of the sebastites verrucosa venom protein neoVTX.

Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include a trimerizing domain (e.g., a collagen 18 trimerizing domain) attached through a peptide linker to a viral protein binding domain (e.g., a spike binding domain). The peptides and trimeric compositions provided herein exhibit a unique trimeric symmetry which results in superior binding affinities and low binding entropies providing for desirable compositions inhibit viral entry and treating viral infection.

The application relates to the field of biological information and discloses a toxic protein library construction method, device, equipment and medium. The method comprises the following steps: acquiring a common peptide structure corresponding to a confirmed toxic protein sequence, and constructing a target toxic protein core peptide set capable of covering a key functional domain of the confirmed toxic protein sequence based on function performance characteristic data and fluctuation trend characteristic data of the common peptide structure. The target toxic protein core peptide set is used for function screening of a to-be-recognized protein sequence in a function characteristic domain, so that an intermediate protein sequence needing to be verified whether it meets a toxicity characteristic is obtained, toxicity screening of the intermediate protein sequence in a toxicity characteristic domain is performed, and the intermediate protein sequence meeting the toxicity characteristic is determined as a target toxic protein sequence. Finally, a toxic protein database is constructed by using the target toxic protein sequence. Thus, a toxic protein library construction method with a wide coverage range which can discover new toxic proteins and detect low-abundance toxic proteins is realized through a two-level screening mode combining function screening and toxicity screening.

The invention relates to molecular biology and genetic engineering technology, and aims to provide a kind of antijatasia venom protein gene VID and application thereof in degradation of drosophila melanogaster tissues. The venom protein genes of the antijatropatella gigantean are named as a venom protein gene VID-1, a venom protein gene VID-2, a venom protein gene VID-3, a venom protein gene VID-4 and a venom protein gene VID-5 respectively, and the nucleotide sequences of the venom protein genes are shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 respectively. The invention discloses the regulation and control function of the antijatropha spp venom protein on the in-vivo tissues of the drosophila larvae for the first time, and experiments verify that the venom protein can specifically induce host adult disc tissues to degrade. Researches prove that the antijatropha opening venom protein can degrade adult disc tissues to prevent fruit flies from eclosion so as to realize pest killing, so that the antijatropha opening venom protein has the value of being applied to agricultural biological control.

The application provides a monoclonal antibody against canine distemper virus N protein and application, first, the application obtains two hybridoma cell strains capable of stably secreting the canine distemper virus monoclonal antibody, which are 1H9B7 and 1D3E9 respectively. Further, the 1H9B7 monoclonal antibody is used as a detection antibody, and the 1D3E9 monoclonal antibody is used as a gold-labeled antibody to prepare a canine distemper virus colloidal gold immunochromatography test strip; the test strip has high sensitivity, strong specificity and good repeatability, and is not prone to missed detection, thereby providing technical support for CDV comprehensive prevention and control.

This invention belongs to the field of microbial technology, specifically disclosing a strain of *Beauveria bassiana* Bp-01, its recombinant strain, and its applications. The *Beauveria bassiana* Bp-01 provided by this invention, with the preservation number CGMCC No. 42442, exhibits strong pathogenicity against the red turpentine beetle and can be used as an excellent biocontrol strain. To further enhance its insecticidal virulence and infection rate, this invention utilizes genetic engineering techniques to successfully construct a recombinant strain Bp, with the preservation number CGMCC No. 42333, by overexpressing the venom protein SERCA in *Beauveria bassiana* Bp-01. Verification showed that compared to the wild-type strain, this recombinant strain infects *Red turpentine beetle* larvae faster, has a higher lethality, and significantly enhanced virulence, further demonstrating stronger infection and colonization capabilities. This invention can be applied to the preparation of biocontrol agents to achieve efficient control of the forest pest, the red turpentine beetle.

The invention relates to the technical field of biology, and provides a spider silk-spider venom protein fusion protein and a modified fiber, the spider silk-spider venom protein fusion protein comprises a spider silk protein or spider silk-like protein and a spider venom protein, and the spider silk-spider venom protein fusion protein is formed by fusion of the spider silk protein or spider silk-like protein and the spider venom protein. Researches find that spider silk proteins have high hydrophilicity and high water solubility and tend to mutually aggregate in a solution to generate liquid-liquid phase separation liquid drops, water-soluble expression of the proteins is greatly improved, the spider silk proteins are used as a functional protein carrier, spider venom proteins are fused on a spider silk protein framework to generate fusion proteins with high water solubility, and the spider silk proteins are used as functional protein carriers. Various soluble spider venom proteins can be produced through microbial fermentation, and the yield of the spider venom proteins is improved, for example, various soluble spider venom proteins can be produced through an escherichia coli expression system.